Navigation Links
Results From IMPROVE Study Show Therapeutic Effect of New Formulation of Rebif(R) at 16 Weeks in Patients With Multiple Sclerosis
Date:9/21/2008

-- Study meets primary endpoint by demonstrating significant effect of new formulation of Rebif(R) on disease activity as measured by MRI after 16

weeks of treatment

-- Data presented at late-breaking session of the World Congress on

Treatment and Research in Multiple Sclerosis in Montreal, Canada

GENEVA, Sept. 22 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that the ongoing IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study met its primary endpoint. The primary objective of the study was to evaluate the efficacy of the new formulation of Rebif(R), compared to placebo, in patients with relapsing-remitting multiple sclerosis (RRMS) and active disease by means of magnetic resonance imaging (MRI) at the end of 16 weeks of treatment. The 16- week study results show that the mean number of combined unique active brain MRI lesions per patient was reduced by 69% in patients treated with the new formulation of Rebif(R) compared with those receiving placebo, a statistically significant result (p<0.001). These data were presented at the late-breaking session of the World Congress on Treatment and Research in Multiple Sclerosis in Montreal, Canada.

"Patients who received Rebif(R) experienced far fewer new active brain MRI lesions than the placebo group after 16 weeks of treatment," said Dr. Mark Freedman, Professor of Neurology at the University of Ottawa, Director of the MS Research Clinic at the Ottawa Hospital, and an investigator of the IMPROVE trial. "These data demonstrate a significant effect of the new formulation of Rebif(R) on disease activity and provide further evidence of its benefit in treating patients with relapsing-remitting multiple sclerosis."

The IMPROVE study is a two-arm, randomized, double-blind, controlled, multicenter, international Phase IIIb study to evaluate the efficacy, safety and tolerability of the new
'/>"/>

SOURCE Merck Serono
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...y 3 Bertalan Mesko, medical blogge...guide for medical professionals focusing on how ...l conferences are expensive and patients are also ...Guide helps doctors enter a virtual realm and orga...s Second Life provides opportunities for case pres...
(Date:7/3/2009)...ivorce or death in middle age may triple the risk,...hDay News) -- Middle-aged adults who live alone ar...,s disease later in life compared to those who are...hree times higher among those who are divorced or ...innish researchers. , The study included 2,000 ...
(Date:7/3/2009)... fireworks hazards , , FRIDAY, July 3 (H... cause almost 10,000 injuries every year in the Un...lp keep you and others safe while enjoying the key...Health Inc. Corporation, which runs several Georgi... fireworks safety: , Obey all local laws regardi...
(Date:7/3/2009)...PRNewswire-Asia/ -- Sundia MediTech, a leading,in...rcing company in Shanghai,China announced today ...,President of Chemistry Services. , Prior t...osciences, a drug,discovery and development compa...cientist to Senior Director of Medicinal Chemistry...
Breaking Medicine News(10 mins):Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Put Safety First on the 4th 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...nd and Amylin Pharmaceuticals has announced that ...ugar levels, at par with iphasic insulin // aspart...revealed after a threadbare study conducted by the...ering type 2 diabetes and unable to control the bl...
... are applying the same basic technique seismologis...chnology that promises to prevent stress fractures...s.// The crack formation generates waves similar ...rchers at Purdue University and the University of ...
...n’s Hospital of Philadelphia announces the establi...sciplinary resource created to diagnose//, treat a...celiac disease. “A person with celiac disease is ...redient found in many foods including bread, pasta...
...ent's campaign had failed to hand out morning-afte...ng number of teenage pregnancies.// The campaign h... Besides this the government has been accused of f...ually transmitted diseases. From 2002 it has been...
Other Medicine News:Health News:New System Monitors Tiny 'Earthquakes' in Bones to Prevent Fractures 2Health News:New System Monitors Tiny 'Earthquakes' in Bones to Prevent Fractures 3Health News:New System Monitors Tiny 'Earthquakes' in Bones to Prevent Fractures 4Health News:Center for Celiac Disease Opens 2Health News:Government Failed to Prevent Rising Teen Pregnancies 2Health News:Government Failed to Prevent Rising Teen Pregnancies 3
(Date:6/29/2009)...Biotherapeutics Based On Naturally Resected tRNA S... -- Pangu BioPharma, a subsidiary of aTyr Pharma i...rd patent application on proprietary, naturally oc...h tRNA synthetases are universal and essential com...l organisms, human synthetases have naturally occu...
(Date:6/28/2009)...tugal, June 29 Data presented,tod...t with the novel,once-daily anti-epileptic Zebin... a marked and sustained decrease in seizure freque...he one-year extension of a pivotal Eslicarbazepine...ternational Congress for Epilepsy in,Budapest, Hu...
(Date:6/26/2009)...Newswire-FirstCall/ -- Sanofi-aventis (EURONEXT:... data associated with a retrospective follow-up of...a clearly show that no definitive conclusions can ...between Lantus(R) (insulin glargine [rDNA] injecti... authors of the study point out. , , Clinical s...
(Date:6/26/2009)...proval of New Anti-TNF Therapy in Three Rheumatic ... , HORSHAM, Pa. and KENILWORTH, N.J., June 26 /PR... and Schering-Plough Corporation (NYSE: SGP ) an...ducts for Human Use (CHMP) of the European Medicin...ending the approval of SIMPONI(TM) (golimumab) as ...
Breaking Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 2Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 3Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 4Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 5Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 6Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R) 7Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 1New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 2New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 3New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 4New Study 3A Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4484 5OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 1OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 2OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 3OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 4OncoGenex Pharmaceuticals Announces OGX 427 Treatment Demonstrates Safety Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Mar 12365 5Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 1Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 2Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 3Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 4Video 3A Phase III Study Data With Vandetanib 28Zactima 28TM 29 29 in Patients With Advanced Non Small Cell Lung Cancer 28NSCLC 29 Presented at Amer 4482 5Wyeth Donates 24100 000 to ASCO Cancer Foundation 28R 29 to Support Cancer Prevention and Care 47367 1Wyeth Donates 24100 000 to ASCO Cancer Foundation 28R 29 to Support Cancer Prevention and Care 47367 2Wyeth Donates 24100 000 to ASCO Cancer Foundation 28R 29 to Support Cancer Prevention and Care 47367 3
...NGTON, March 15, 2007 /PRNewswire/ -- Up to two mi...h up to 600,000,hospitalized. Its primary complica...0 lives annually -- more than breast cancer and,AI...Thrombosis (DVT) recently,sponsored an online surv...ers and physicians. The survey, which was conducte...
...ng-Plough Announces Presentation Of Phase II Trial...st At The 2007 Annual,Meeting Of The American Coll...ch 16, 2007 /PRNewswire-FirstCall/ --,Schering-Plo...e,Phase II trial of its novel oral thrombin recept...t the 2007 annual Scientific Sessions,of the of Ca...
Other Medicine Technology:DVT Awareness Survey Findings for Respondents in High-Risk Groups:,Obese Individuals 2Media Advisory: ACC Updated Schedule 2
Siemens Video: Smart Heart Scans for Athletes
The VPAP III ST-A combines the exclusive features of the popular VPAP III series with adjustable trigger and cycle thresholds and a full range of clinician and patient-friendly alarms in a new, strea
Siemens Webcast: Cardiovascular Computed Tomography (CVCT): A Cardiologists Perspective
GeroFlex reusable catheters for 24-hour esophageal pH monitoring. , ,The GeroFlex esophageal pH catheters are reusable up to five times. They are constructed of the same high quality materials as t
Medicine Products: